Jenburkt Pharma

Which are the latest news on Jenburkt Pharma?

Why is Jenburkt Pharmaceuticals Ltd falling/rising?

As of 05-Sep, Jenburkt Pharmaceuticals Ltd's stock price has declined to 1,034.40, reflecting a -0.54% change. This decline is due to significant underperformance over the past year, disappointing quarterly results, and poor long-term growth prospects, leading to a lack of investor confidence.

As of 05-Sep, Jenburkt Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 1,034.40, which reflects a change of -5.65 (-0.54%). This downward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed significantly over the past year, generating a return of -11.05%, while the broader market (BSE500) has yielded a positive return of 1.51%. This stark contrast indicates a lack of investor confidence in the company's growth prospects. Additionally, the company's recent quarterly performance has shown concerning declines, with profit before tax (PBT) falling by -47.6%, profit after tax (PAT) down by -37.8%, and net sales decreasing by -15.8% compared to previous quarters. These figures suggest that the company is struggling to maintain its revenue and profitability levels.<BR><BR>Moreover, despite a high return on equity (ROE) of 18.98% and being net-debt free, the company has shown poor long-term growth, with net sales growing at an annual rate of only 7.22% over the last five years. This lack of robust growth may lead investors to view the stock as less attractive, contributing to its declining price.<BR><BR>In terms of market performance, Jenburkt Pharmaceuticals is trading below its moving averages across various time frames, indicating a bearish trend. Although there has been a rise in investor participation, with delivery volume increasing by 189.49% against the 5-day average, this has not translated into a positive price movement.<BR><BR>Overall, the combination of underperformance relative to the market, disappointing quarterly results, and poor long-term growth prospects are key factors driving the decline in Jenburkt Pharmaceuticals Ltd's stock price.

Who are in the management team of Jenburkt Pharma?

The management team of Jenburkt Pharma includes Ashish U Bhuta (Chairman & Managing Director), Dilip H Bhuta (Whole Time Director & CFO), and Ashish R Shah (Company Secretary & Compliance Officer), along with several Non-Executive and Independent Directors. This team combines executive leadership with independent oversight.

The management team of Jenburkt Pharma includes the following individuals:<BR><BR>1. **Ashish U Bhuta** - Chairman & Managing Director<BR>2. **Dilip H Bhuta** - Whole Time Director & CFO<BR>3. **Ashish R Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the Board of Directors features several Non-Executive and Independent Directors:<BR><BR>1. **Bharat V Bhate**<BR>2. **Rameshchandra J Vora**<BR>3. **Arun R Raskapurwala**<BR>4. **Hina Ravindra Mehta**<BR>5. **Sumit Ajaybhai Thakkar**<BR><BR>This team brings a mix of executive leadership and independent oversight to the company.

What does Jenburkt Pharma do?

Jenburkt Pharmaceuticals Ltd manufactures and markets specialty pharmaceutical formulations and healthcare products. As of June 2026, it reported net sales of 36 Cr and a net profit of 6 Cr, with a market cap of INR 481 Cr.

Overview: <BR>Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing and marketing of specialty and high-quality pharmaceutical formulations and healthcare products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1985, Jenburkt Pharmaceuticals was formed as a joint venture by the Bhuta family to diversify into the healthcare and pharmaceutical industry. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 36 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 6 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 481 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.27 <BR>Return on Equity: 18.25% <BR>Price to Book: 2.36 <BR><BR>Contact Details: <BR>Address: Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W) Mumbai Maharashtra : 400058 <BR>Tel: 91-22-66943121/67603603 <BR>Email: investor@jenburkt.com <BR>Website: http://www.jenburkt.com

Who are the peers of the Jenburkt Pharma?

Jenburkt Pharma's peers include Bafna Pharma, Kilitch Drugs, Valiant Laborato, Albert David, Transchem, Haleos Labs, Medico Remedies, Ambalal Sarabhai, and Infinium Pharma. Bafna Pharma leads with a 1-year return of 198.53%, while Jenburkt Pharma has a -4.08% return.

Peers: The peers of Jenburkt Pharma are Bafna Pharma., Kilitch Drugs, Valiant Laborato, Albert David, Transchem, Haleos Labs Limi, Medico Remedies, Ambalal Sarabhai, and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jenburkt Pharma and Medico Remedies, while Average management risk is found at Kilitch Drugs, Albert David, Transchem, and Haleos Labs Limi. Below Average management risk is noted for Bafna Pharma., Valiant Laborato, Ambalal Sarabhai, and Infinium Pharma. For Growth, Good growth is seen at Kilitch Drugs and Medico Remedies, while Below Average growth is reported for Jenburkt Pharma, Bafna Pharma., Valiant Laborato, Albert David, Transchem, Haleos Labs Limi, Ambalal Sarabhai, and Infinium Pharma. Average capital structure is found at Bafna Pharma., Transchem, Haleos Labs Limi, and Ambalal Sarabhai, while Excellent capital structure is noted for Jenburkt Pharma, Albert David, and Infinium Pharma, with Average capital structure at the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bafna Pharma. at 198.53%, while Jenburkt Pharma has a 1-year return of -4.08%, which is significantly lower than Bafna Pharma.'s. Additionally, Medico Remedies and Transchem have negative six-month returns.

How big is Jenburkt Pharma?

As of 31st August, Jenburkt Pharmaceuticals Ltd has a market capitalization of 481.00 Cr, with recent net sales of 168.72 Cr and net profit of 32.83 Cr over the last four quarters.

As of 31st August, <BR><BR>Market Cap: Jenburkt Pharmaceuticals Ltd has a market capitalization of 481.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 168.72 Cr, while the sum of Net Profit for the same period is 32.83 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2026, with Shareholder's Funds amounting to 197.04 Cr and Total Assets valued at 223.61 Cr.

Should I buy, sell or hold Jenburkt Pharmaceuticals Ltd.?

When is the next results date for Jenburkt Pharmaceuticals Ltd.?

The next results date for Jenburkt Pharmaceuticals Ltd. is August 6, 2026.

The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for August 6, 2026.

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

Jenburkt Pharmaceuticals Ltd. reported strong Q4 FY26 results, with a net profit of ₹10.85 crores, an 82.97% quarter-on-quarter increase, and a revenue of ₹44.63 crores, reflecting solid growth. The company also improved its operating margins significantly and maintains a debt-free balance sheet, indicating a positive financial position overall.

Jenburkt Pharmaceuticals Ltd. has reported strong results for Q4 FY26, indicating a positive performance overall. The company achieved a net profit of ₹10.85 crores, which marks an impressive 82.97% increase compared to the previous quarter and a 27.05% increase year-on-year. This significant growth in net profit is complemented by a revenue of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% and an 8.72% increase year-on-year.<BR><BR>One of the standout features of this quarter is the remarkable recovery in operating margins, which rose to 31.93%, up from 17.25% in the previous quarter. This increase of 1,468 basis points is primarily attributed to a substantial reduction in employee costs, suggesting improved operational efficiency.<BR><BR>Overall, the financial performance showcases strong capital efficiency, with a return on equity (ROE) of 18.99%. The company's debt-free balance sheet further enhances its financial stability. Given these results, Jenburkt Pharmaceuticals appears to be in a good position, demonstrating both profitability and effective cost management. However, the sustainability of these margins and revenue growth will be crucial to monitor in future quarters.

Is Jenburkt Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish, indicated by daily moving averages and monthly MACD, despite mixed signals from the KST and a lack of strong bullish indicators in the RSI and Dow Theory.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the monthly MACD showing a mildly bearish outlook. The weekly Bollinger Bands also reflect a bearish trend, while the KST presents a mixed view with a mildly bullish weekly signal but a mildly bearish monthly signal. Overall, the lack of strong bullish signals in the RSI and Dow Theory further supports the mildly bearish stance.

How has been the historical performance of Jenburkt Pharma?

Jenburkt Pharma has shown consistent growth in net sales and profits, with net sales increasing from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, and profit after tax rising from INR 16.50 crore to INR 32.06 crore during the same period, indicating strong financial health.

Answer:<BR>The historical performance of Jenburkt Pharma shows a consistent growth trend in net sales and profits over the years.<BR><BR>Breakdown:<BR>Jenburkt Pharma's net sales have steadily increased from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, reflecting a strong upward trajectory. The total operating income followed a similar pattern, rising from INR 118.89 crore in March 2020 to INR 151.69 crore in March 2025. Operating profit (PBDIT) also saw significant growth, climbing from INR 24.15 crore in March 2021 to INR 47.11 crore in March 2025, indicating improved operational efficiency. Profit before tax rose from INR 21.64 crore in March 2021 to INR 43.93 crore in March 2025, while profit after tax increased from INR 16.50 crore to INR 32.06 crore during the same period. The company's earnings per share (EPS) improved from INR 35.95 in March 2021 to INR 72.7 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 104.31 crore in March 2020 to INR 194.72 crore in March 2025, with total liabilities also increasing but at a controlled pace. Cash flow from operating activities improved significantly, reaching INR 27 crore in March 2025, compared to INR 8 crore in March 2024, while the closing cash and cash equivalents rose to INR 7 crore in March 2025 from INR 4 crore in March 2024. Overall, Jenburkt Pharma has demonstrated robust financial health and growth across multiple dimensions over the years.

Is Jenburkt Pharma overvalued or undervalued?

As of October 23, 2025, Jenburkt Pharma is considered overvalued with a PE ratio of 14.79 and an EV to EBIT of 12.31, despite outperforming the Sensex, indicating caution for potential investors.

As of 23 October 2025, Jenburkt Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 14.79, an EV to EBIT of 12.31, and an ROCE of 23.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.47, while Cipla is valued more attractively with a PE of 24.64.<BR><BR>The valuation metrics suggest that Jenburkt Pharma is trading at a premium relative to its earnings potential, especially when considering the PEG ratio of 0.94, which indicates growth at a reasonable price but still reflects a higher valuation compared to peers like Dr Reddy's Labs, which boasts a PE of 18.8 and an EV to EBITDA of 12.41. While Jenburkt Pharma has outperformed the Sensex over the past year with a return of 12.62% compared to the Sensex's 5.59%, the overall valuation suggests caution for potential investors.

Who are the top shareholders of the Jenburkt Pharma?

The top shareholders of Jenburkt Pharma are Bhuta Holdings Private Limited with 13.96%, and individual investors who collectively own 43.55%. The largest public shareholder is Nirmala Vinodkumar Daga, holding 3.3%, with no institutional investors currently involved.

The top shareholders of Jenburkt Pharma include Bhuta Holdings Private Limited, which holds the highest stake at 13.96%. Additionally, individual investors collectively own 43.55% of the company. The highest public shareholder is Nirmala Vinodkumar Daga, with a holding of 3.3%. There are no institutional investors or mutual funds currently holding shares in the company.

Has Jenburkt Pharma declared dividend?

Yes, Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend, with an ex-date of July 23, 2024. Despite this significant dividend announcement, the dividend yield remains at 0%, while the company has shown strong price appreciation over various periods.

Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 153%<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 4.19%, with a dividend return of 0%, resulting in a total return of 4.19%.<BR><BR>Over the past year, the price return was 55.55%, with a dividend return of 0%, leading to a total return of 55.55%.<BR><BR>In the 2-year period, the price return was 79.44%, with a dividend return of 0%, culminating in a total return of 79.44%.<BR><BR>For the 3-year period, the price return was 135.81%, with a dividend return of 2.48%, resulting in a total return of 138.29%.<BR><BR>In the 4-year period, the price return was 150.9%, with a dividend return of 4.55%, leading to a total return of 155.45%.<BR><BR>Over the last 5 years, the price return was 238.92%, with a dividend return of 6.11%, culminating in a total return of 245.03%.<BR><BR>Overall, Jenburkt Pharmaceuticals Ltd. has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting positive performance in the company's stock value.